Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Zevra Therapeutics has a consensus analyst rating of “Moderate Buy”, with eight buy ratings and one hold rating among nine research firms. The average 1-year price target is about $23.33.
• The company beat expectations in its latest quarterly results, reporting EPS of $0.18 versus the expected $0.06 and revenue of $36.22 million versus estimates of $31.96 million. Analysts now expect full-year EPS of $0.52.
• Recent analyst updates and estimate revisions have been mostly positive, including Guggenheim raising its price target to $25 and HC Wainwright lifting earnings forecasts for 2026, 2027, and 2030. Institutional ownership also remains meaningful, with hedge funds and other institutions holding 35.03% of the stock.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $23.3333.

A number of equities research analysts recently commented on ZVRA shares. Guggenheim increased their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Friday. Wall Street Zen raised shares of Zevra Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, April 11th. BTIG Research began coverage on shares of Zevra Therapeutics in a research note on Monday, March 16th. They set a "buy" rating and a $23.00 price target on the stock. Finally, Weiss Ratings raised shares of Zevra Therapeutics from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Friday.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA opened at $11.13 on Monday. The stock has a market cap of $658.01 million, a price-to-earnings ratio of 5.59 and a beta of 0.88. Zevra Therapeutics has a 52 week low of $7.16 and a 52 week high of $13.16. The company's 50-day moving average price is $9.73 and its 200 day moving average price is $9.25.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.12. The firm had revenue of $36.22 million for the quarter, compared to analysts' expectations of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. As a group, research analysts expect that Zevra Therapeutics will post 0.52 earnings per share for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds have recently modified their holdings of the company. CWM LLC boosted its stake in shares of Zevra Therapeutics by 399.5% during the 3rd quarter. CWM LLC now owns 2,872 shares of the company's stock worth $27,000 after purchasing an additional 2,297 shares during the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in shares of Zevra Therapeutics during the 4th quarter worth about $53,000. Russell Investments Group Ltd. boosted its stake in shares of Zevra Therapeutics by 235.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company's stock worth $61,000 after purchasing an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Zevra Therapeutics by 617.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company's stock worth $88,000 after purchasing an additional 8,552 shares during the last quarter. Finally, Creative Planning acquired a new stake in shares of Zevra Therapeutics during the 2nd quarter worth about $92,000. 35.03% of the stock is owned by institutional investors and hedge funds.

Key Zevra Therapeutics News

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: HC Wainwright raised Zevra’s Q2 2026 EPS estimate to $0.06 from $0.03, signaling better near-term earnings expectations.
• Positive Sentiment: The firm also increased Q3 2026 EPS estimates to $0.11 from $0.08 and Q4 2026 EPS estimates to $0.17 from $0.12, reflecting stronger expected profitability.
• Positive Sentiment: HC Wainwright lifted its FY2027 and FY2030 earnings forecasts, suggesting confidence in Zevra’s long-term growth trajectory.
• Neutral Sentiment: One analyst lowered FY2028 and FY2029 estimates slightly, but the changes were modest and did not offset the broader upward revisions. Zevra Therapeutics stock page

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.